Vera Therapeutics Inc (VERA)
41.38
-0.56
(-1.34%)
USD |
NASDAQ |
May 17, 16:00
41.38
0.00 (0.00%)
After-Hours: 20:00
Vera Therapeutics Cash from Investing (TTM): -270.95M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -270.95M |
December 31, 2023 | -39.43M |
September 30, 2023 | -44.55M |
June 30, 2023 | -63.22M |
March 31, 2023 | -18.86M |
December 31, 2022 | -70.55M |
September 30, 2022 | -88.99M |
Date | Value |
---|---|
June 30, 2022 | -86.55M |
March 31, 2022 | -43.66M |
December 31, 2021 | -4.204M |
September 30, 2021 | 0.853M |
June 30, 2021 | 0.853M |
March 31, 2021 | 0.01M |
December 31, 2020 | -0.042M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-270.95M
Minimum
Mar 2024
0.853M
Maximum
Jun 2021
-52.09M
Average
-41.54M
Median
Cash from Investing (TTM) Benchmarks
Vertex Pharmaceuticals Inc | -3.444B |
Alpine Immune Sciences Inc | -86.47M |
Fate Therapeutics Inc | 120.64M |
Mersana Therapeutics Inc | 45.94M |
Equillium Inc | 17.59M |